Ladetto, M <br/><br/>
Concurrent administration of high-dose chemotherapy and rituximab is a feasible and effective chemo/immunotherapy for patients with high-risk non-Hodgkin's lymphoma.  [electronic resource] 

 -  Leukemia  Dec 2001 
 - 1941-9 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>0887-6924 
<br/><br/><label>Standard No.: </label>10.1038/sj.leu.2402302  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Antibodies, Monoclonal--administration & dosage<br/>Antibodies, Monoclonal, Murine-Derived<br/>Antineoplastic Combined Chemotherapy Protocols--administration & dosage<br/>Drug Administration Schedule<br/>Feasibility Studies<br/>Female<br/>Hematopoietic Stem Cell Transplantation<br/>Humans<br/>Immunotherapy<br/>Lymphoma, Non-Hodgkin--complications<br/>Male<br/>Middle Aged<br/>Neoplasm, Residual--diagnosis<br/>Polymerase Chain Reaction<br/>Rituximab<br/>Salvage Therapy<br/>Transplantation, Autologous<br/>Treatment Outcome